Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Ramzi Hamouche, Francine M. Foss, Sayeef Mirza, Mengyang Di, Iris Isufi, Noffar Bar, Lohith Gowda, Sarah Perreault, Kenneth Roberts, Stuart Seropian, Tarsheen Sethi

Blood (2023) 142 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2023-189414

Published: 2023

Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2023-181762

Published: 2023

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

Blood (2022) 140 (Supplement 1): 4633–4635.

https://doi.org/10.1182/blood-2022-163750

Published: 2022

Journal Articles

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Guru Subramanian Guru Murthy, Brent R. Logan, Stephanie Bo-Subait, Amer Beitingjaneh, Steven Devine, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A. Yared, Heather E. Stefanski, Michael A. Pulsipher, Jack W. Hsu, Galen E. Switzer, Sandhya R. Panch, Bronwen E. Shaw

Blood (2021) 138 (Supplement 1): 907.

https://doi.org/10.1182/blood-2021-150635

Published: 2021

Journal Articles

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Blood (2021) 138 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2021-154151

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Megan Lee, BS, Molly Schiffer, PharmD, Iris Isufi, MD, Scott F. Huntington, MD MPH, Mina L. Xu, MD, Stuart Seropian, MD, Lohith Gowda, MD, Shalin K. Kothari, MD, Michael Girardi, MD PhD, Francine M. Foss, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139790

Published: 2020

Journal Articles

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Sagar Patel, MD, Saulius K. Girnius, MD, Binod Dhakal, MBBS, Lohith Gowda, MD, Raphael Fraser, PhD, Omar Davila, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Shaji K. Kumar, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD

Blood (2019) 134 (Supplement_1): 266.

https://doi.org/10.1182/blood-2019-127049

Published: 2019

Journal Articles

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Namrata S Chandhok, MD, Scott F. Huntington, MD MPH, Iris Isufi, MD, Lohith Gowda, MD MRCP, Mina L Xu, MD, Noffar Bar, MD, Stuart Seropian, MD, Francine M. Foss, MD

Blood (2019) 134 (Supplement_1): 4055.

https://doi.org/10.1182/blood-2019-128888

Published: 2019

Journal Articles

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Lohith Gowda, MD MRCP, Karl Hager, PhD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5173.

https://doi.org/10.1182/blood-2019-127162

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

Journal Articles

Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival

Blood (2017) 130 (Supplement 1): 3267.

https://doi.org/10.1182/blood.V130.Suppl_1.3267.3267

Published: 2017

Journal Articles

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Abdul Rashid Shah, MD, Tariq Muzzafar, MBBS, Romana Asad, MD, Christine B Peterson, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD, Nitin Jain, MD, Gautam Borthakur, MD, Maliha Khan, MD, Abhishek Chilkulwar, MD, Brion Randolph, MD, Lohith Gowda, MD, Michael J Keating

Blood (2017) 130 (Supplement 1): 5337.

https://doi.org/10.1182/blood.V130.Suppl_1.5337.5337

Published: 2017

Journal Articles

Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients

Blood (2017) 130 (Supplement 1): 1992.

https://doi.org/10.1182/blood.V130.Suppl_1.1992.1992

Published: 2017

NARROW

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only